Clinical trial
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or…
NCT01721746 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT01721746 |
|---|---|
| Title | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) |
| Official title | A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Unresectable or Metastatic Melanoma |
| Intervention type | Biological, Drug |
| Interventions | BMS-936558, Dacarbazine, Carboplatin, Paclitaxel |
| Enrollment | 405 |
| Start date | Dec 21, 2012 |
| Primary completion | Feb 16, 2016 |
| Completion | Dec 29, 2020 |
| First posted | Nov 6, 2012 |
| Last update posted | Apr 19, 2022 |
| Countries | Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: